Navigation Links
Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
Date:11/8/2007

HOUSTON, Nov. 8 /PRNewswire-USNewswire/ -- US Oncology, who supports one of the nation's largest cancer treatment and research networks representing over 1,100 oncologists nationwide, supports the FDA's label outlining the safe and effective administration of ESAs at the minimum level of the range 10-12 grams per deciliter (gm/dL), a declaration that has long been a central part of the US Oncology physician network's recommended clinical guidelines.

Recently, a number of health concerns have arisen for ESA dosing levels exceeding 12 gm/dL. The FDA's new label repeatedly notes the upper safety limit is 12 gm/dL, and preserves physician discretion to use the lowest dose possible in order to avoid blood transfusions - widely regarded as cumbersome for patients and carry several health risks -- and to continue treatment within the range of 10-12 gm/dL.

Physician discretion remains the critical point of debate. The current FDA labeling provides flexibility for patients and physicians to decide whether the use of ESAs is appropriate for each individual case. These considerations may include the type and anticipated duration of chemotherapy and its known impact on blood cell reproduction.

The new FDA label supports anemia management protocols adopted by US Oncology, the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the European Agency for the Evaluation of Medicinal Products (EMEA), and all major U.S. health insurance plans. All of these groups support the same physician-centric approach and reflect a target range of 10 gm/dL and 12 gm/dL. This treatment range stands in contrast only to the National Coverage Determination (NCD) recently adopted by the Centers for Medicare and Medicaid Services (CMS), which denies coverage for ESAs above the hemoglobin levels of 10 gm/dL.

US Oncology and its affiliated network of physicians continue to be concerned that the NCD interferences with medically-evidenced treatment protocols for cancer patients and creates a two-tiered health care system based on insurance -- one for patients with Medicare and one for patients with private insurance. Under the new CMS NCD policy, Medicare beneficiaries risk reaching hemoglobin levels oncologists regard as inappropriately low for health a safety, and as a result, will risk blood transfusion.

One new warning in the FDA label states, "the risks of shortened survival and tumor promotion have not been excluded when ESAs are dosed to target a hemoglobin of < 12 gm/dL." While US Oncology agrees with the accuracy of this statement, numerous clinical trials looking at adverse events in the 10-12 gm/dL range have found no evidence of reduced mortality or tumor progression.

Given this new label, US Oncology maintains that patients should continue to review the risks and benefits of the most safe and effective anemia management protocol with their physician while undergoing chemotherapy to treat their individual disease.


'/>"/>
SOURCE US Oncology
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
4. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
5. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
6. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
9. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
10. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
11. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that Frost & ... Innovation Award for Its fibromyalgia pain management device. The ... market research by Frost & Sullivan,s industry experts. ... product, the AVACEN 100, offers a safe and effective solution ... ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm ... California Berkeley, and other leading institutions in announcing the launch of the ... change the way animals are raised for food. , Founding members of the ...
Breaking Medicine News(10 mins):